EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Isavuconazole as primary antifungal prophylaxis in pediatric hematological patients: a clinical and pharmacokinetic analysis

Francesco Baccelli, Caterina Campoli, Martina Colli iD, Milo Gatti iD, Francesca Gottardi, Gennaro Pagano, Francesco Venturelli, Davide Leardini, Edoardo Muratore, Gianluca Bossù, Federico Pea iD, Pierluigi Viale und 4 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00451-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Francesco Baccelli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Antifungal Agents, Nitriles, Triazoles, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Invasive fungal diseases (IFDs) are a major threat in pediatric patients with hematologic malignancies (HMs) and hematopoietic stem cell transplantation (HSCT) recipients. Optimal antifungal prophylaxis (AFP) remains a clinical challenge. Isavuconazole (ISA), a broad-spectrum triazole, may offer a safer, more predictable option for AFP in this setting, but pediatric data are scarce. We retrospectively analyzed pediatric patients (≤18 years) with HM or HSCT who received isavuconazole as primary AFP from January 2021 to April 2025 at a single center. Isavuconazole dosing, therapeutic drug monitoring (TDM), safety, and breakthrough IFD incidence were systematically evaluated in a standardized stewardship framework. Isavuconazole was administered as primary antifungal prophylaxis in 21 patients (median age 9.6 years), 17 (77.3 %) after HSCT. Doses were weight-adjusted (100 or 200 mg/day) with loading over 48 h. No severe adverse events attributable to isavuconazole were reported. No breakthrough IFDs occurred during prophylaxis. Concomitant use of CYP3A4-interacting agents (e.g., ruxolitinib) was not associated with increased toxicity or isavuconazole level alterations. TDM was performed in all patients (188 total measurements); median Cmin was 3.4 mg/L. The target range (1–5 mg/L) was achieved in 95.2% of first TDMs. Dosage adjustments were needed in only 5.9% of cases, indicating consistent pharmacokinetics. In this retrospective cohort of high-risk pediatric hematology patients, isavuconazole used as primary antifungal prophylaxis showed favorable safety, consistent drug exposure, and no breakthrough IFDs. These findings support further prospective evaluation of isavuconazole in pediatric prophylactic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsNitrilesTriazolesPyridinesInvasive Fungal InfectionsHematologic NeoplasmsHumansChildFemaleRetrospective StudiesMaleAdolescentHematopoietic Stem Cell TransplantationChild, PreschoolDrug Monitoring

Stichwörter der Autor:innen

antifungal prophylaxiscancerhematologyhematopoietic stem cell transplantationinvasive fungal diseaseisavuconazoleoncologypediatrictherapeutic drug monitoring

Substanzen

isavuconazoleAntifungal AgentsNitrilesTriazolesPyridines

Autor:innen und Institutionen

  • Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
  • Department of Pediatric Hematology-Oncology, Azienda Unità Sanitaria Locale di Rimini, Rimini, Italy.

ORCID-Profile: Martina Colli, Milo Gatti, Federico Pea

Förderung

  • Ministero della Salute

Zitieren

APA

Baccelli, F., Campoli, C., Colli, M., Gatti, M., Gottardi, F., Pagano, G., Venturelli, F., Leardini, D., Muratore, E., Bossù, G., Pea, F., Viale, P., Giannella, M., Belotti, T., Prete, A., & Masetti, R. (2026). Isavuconazole as primary antifungal prophylaxis in pediatric hematological patients: a clinical and pharmacokinetic analysis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00451-26

Vancouver

Baccelli F, Campoli C, Colli M, Gatti M, Gottardi F, Pagano G, et al. Isavuconazole as primary antifungal prophylaxis in pediatric hematological patients: a clinical and pharmacokinetic analysis. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00451-26

BibTeX
@article{Baccelli2026,
  author = {Baccelli, Francesco and Campoli, Caterina and Colli, Martina and Gatti, Milo and Gottardi, Francesca and Pagano, Gennaro and Venturelli, Francesco and Leardini, Davide and Muratore, Edoardo and Bossù, Gianluca and Pea, Federico and Viale, Pierluigi and Giannella, Maddalena and Belotti, Tamara and Prete, Arcangelo and Masetti, Riccardo},
  title = {Isavuconazole as primary antifungal prophylaxis in pediatric hematological patients: a clinical and pharmacokinetic analysis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00451-26}
}
Kostenlos starten →